PDF(4031 KB)
C1q肿瘤坏死因子相关蛋白3(C1QTNF3)在肝癌中的表达及其对预后的预测价值
金丽莹, 王姝涵, 杨洋
PDF(4031 KB)
PDF(4031 KB)
C1q肿瘤坏死因子相关蛋白3(C1QTNF3)在肝癌中的表达及其对预后的预测价值
The expression of C1QTNF3 in liver cancer and its prognostic value
目的 探究C1q肿瘤坏死因子相关蛋白3(C1QTNF3)在肝癌组织中的表达情况,分析其与患者临床病理特征的关系,并进一步评估其在肝癌预后中的潜在预测价值。 方法 分别于TIMER、UALCAN、TNMplot及GEO数据库收集资料,采用生物信息学分析C1QTNF3基因在泛癌、正常组织与肝癌组织,以及癌组织及其癌旁组织中的表达水平。选取90例肝癌患者的肝癌组织及其癌旁组织标本,收集患者年龄、性别、肿瘤直径、肿瘤数目等临床资料。计量资料组间比较采用成组t检验或配对t检验;计数资料组间比较采用χ2检验。Kaplan-Meier法绘制生存曲线,Log-rank检验分析C1QTNF3表达水平与肝癌患者生存期的关系。Cox回归模型分析影响肝癌患者预后的危险因素,受试者操作特征曲线(ROC曲线)分析不同时间点C1QTNF3表达对肝癌患者预后的预测能力。 结果 生物信息学分析结果显示,C1QTNF3基因在多种恶性肿瘤组织中表达上调,尤其在肝癌组织中(P<0.001);C1QTNF3基因在肝癌组织中的表达量高于正常组织及其癌旁组织(P值均<0.01)。90例肝癌患者免疫组化染色结果显示,C1QTNF3主要表达于细胞质,少量表达于细胞核,且在癌旁组织中主要呈阴性表达,在肝癌组织中呈阳性表达。C1QTNF3蛋白在肝癌组织中的阳性表达率(76.67% vs 33.33%)和强阳性表达率(54.44% vs 5.56%)均显著高于癌旁组织(χ2值分别为34.141、51.217,P值均<0.01)。肿瘤直径≥5 cm、晚期、肝硬化、HBsAg阴性和GGT≥50 U/L肝癌患者的C1QTNF3蛋白强阳性表达率均显著高于肿瘤直径<5 cm、早期、无肝硬化、HBsAg阳性和GGT<50 U/L的肝癌患者(P值均<0.05)。单因素Cox回归分析结果显示,肿瘤直径、复发情况和C1QTNF3表达是肝癌患者预后的影响因素(P值均<0.05);多因素Cox回归分析结果显示,C1QTNF3表达水平和复发情况是影响肝癌患者生存期的独立危险因素(P值均<0.05)。生存曲线结果显示,所有肝癌患者中,C1QTNF3高表达(强阳性)者相较于低表达者,总生存率和无瘤生存率均更短(χ2值分别为17.010、13.647,P值均<0.001);在肿瘤直径≥5 cm、早/晚期、复发、肝硬化、HBsAg阳性、ALT<40 U/L、ALT≥40 U/L和GGT≥50 U/L的肝癌患者中,C1QTNF3高表达者的总生存率均显著降低(χ2值分别11.086、5.578、5.295、19.159、16.391、13.774、10.119、8.152、12.035,P值均<0.05)。ROC曲线结果显示,C1QTNF3表达在5年时的预测潜力最强,ROC曲线下面积为0.77。 结论 C1QTNF3在肝癌组织中呈高表达,其表达水平和复发情况与肝癌患者的生存期密切相关,C1QTNF3蛋白高表达患者生存率更低。
Objective To investigate the expression of C1q tumor necrosis factor-related protein 3 (C1QTNF3) in liver cancer tissue,its association with the clinicopathological features of patients,and its potential value in predicting the prognosis of liver cancer. Methods Related data were collected from TIMER,UALCAN,TNMplot,and GEO databases,and the bioinformatics methods were used to measure the expression level of C1QTNF3 in pan-cancer,normal tissue/liver cancer tissue,and cancerous tissue/paracancerous tissue. Cancerous and paracancerous tissue samples were collected from 90 patients with liver cancer,and related clinical data were collected,including age,sex,tumor diameter,and tumor number. The independent-samples t test or the paired t-test was used for comparison of continuous data between groups,and the chi-square test was used for comparison of categorical data between groups. The Kaplan-Meier method was used to plot survival curves,and the Log-rank test was used to investigate the association between the expression level of C1QTNF3 and the survival of patients with liver cancer. The Cox regression model was used to identify the risk factors for the prognosis of patients with liver cancer,and the receiver operating characteristic (ROC) curve was used to analyze the ability of C1QTNF3 expression at different time points for predicting the prognosis of patients with liver cancer. Results The bioinformatics analysis showed that the expression of C1QTNF3 was upregulated in various malignant tumors,especially in liver cancer tissue (P<0.001),and the expression level of C1QTNF3 in liver cancer tissue was significantly higher than that in normal tissue and paracancerous tissues (all P<0.01). The immunohistochemical staining results of 90 patients with liver cancer showed that C1QTNF3 was mainly expressed in cytoplasm,with a small amount in nucleus,and it had negative expression in paracancerous tissue and positive expression in liver cancer tissue. The positive expression rate and strong positive expression rate of C1QTNF3 protein in liver cancer tissue were significantly higher than those in paracancerous tissue (positive expression rate: 76.67% vs 33.33%,χ2=34.141,P<0.01; strong positive expression rate: 54.44% vs 5.56%,χ2=51.217,P<0.01). The liver cancer patients with a tumor diameter of ≥5 cm,an advanced stage,the presence of liver cirrhosis,negative HBsAg,and gamma-glutamyl transpeptidase (GGT)≥50 U/L had a significantly higher strong positive expression rate of C1QTNF3 protein than those with a tumor diameter of <5 cm,an early stage,the absence of liver cirrhosis,positive HBsAg,and GGT<50 U/L (all P<0.05). The univariate Cox regression analysis showed that tumor diameter,recurrence,and C1QTNF3 expression were influencing factors for the prognosis of patients with liver cancer (all P<0.05),and the multivariate Cox regression analysis showed that the expression level of C1QTNF3 and recurrence were independent risk factors for the survival of patients with liver cancer (both P<0.05). The survival curve analysis showed that for all patients with liver cancer,the patients with high (strong positive) expression of C1QTNF3 had significantly lower overall survival rate and disease-free survival rate than those with low expression (χ2=17.010 and 13.647,both P<0.001); for liver cancer patients with a tumor diameter of ≥5 cm,an early/advanced stage,recurrence,the presence of liver cirrhosis,positive HBsAg,alanine aminotransferase (ALT) <40 U/L,ALT≥40 U/L,and GGT≥50 U/L,the patients with high expression of C1QTNF3 had a significant reduction in overall survival rate (χ2=11.086,5.578,5.295,19.159,16.391,13.774,10.119,8.152,and 12.035,all P<0.05). The ROC curve analysis showed that C1QTNF3 expression had the strongest predictive potential at 5 years,with an area under the ROC curve of 0.77. Conclusion C1QTNF3 is highly expressed in liver cancer tissue,and the expression level of C1QTNF3 and recurrence are closely associated with the survival of patients with liver cancer. Patients with high expression of C1QTNF3 protein tend to have a lower survival rate.
| [1] |
|
| [2] |
侯志远, 刘源, 杨超然, 等. 循环肿瘤DNA在肝细胞癌中的研究现状及展望[J]. 临床肝胆病杂志, 2022, 38(11): 2616-2620. DOI: 10.3969/j.issn.1001-5256.2022.11.036.
|
| [3] |
冉小柯, 陈欣菊, 赵云霞, 等. 叉头转录因子A2、J2在肝细胞癌组织中的表达及意义[J]. 临床肝胆病杂志, 2021, 37(6): 1342-1347. DOI: 10.3969/j.issn.1001-5256.2021.06.025.
|
| [4] |
余学海, 陈本栋, 刘伊敏, 等. NOD样受体蛋白3(NLRP3)炎性小体在肝细胞癌发生发展中的作用[J]. 临床肝胆病杂志, 2024, 40(2): 397-401. DOI: 10.12449/JCH240229.
|
| [5] |
李姣姣, 杨会会, 霍刚. 原发性肝癌患者临床特征、细胞形态学分析及其预后的影响因素分析[J]. 临床和实验医学杂志, 2024, 23(6): 566-570. DOI: 10.3969/j.issn.1671-4695.2024.06.002.
|
| [6] |
郭佩, 卢旺, 杨文轩, 等. 药物性肝损伤相关生物学标志物的研究进展[J]. 临床肝胆病杂志, 2016, 32(9): 1822-1826. DOI: 10.3969/j.issn.1001-5256.2016.09.043.
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
郑卫萍, 沈中阳. 肝细胞癌肝移植术后肿瘤复发的危险因素与防治策略[J]. 临床肝胆病杂志, 2019, 35(11): 2391-2395. DOI: 10.3969/j.issn.1001-5256.2019.11.003.
|
| [14] |
王天然, 许爱国, 陈莉, 等. 血清GLS和AFP联合测定对原发性肝癌诊断的意义[J]. 临床肝胆病杂志, 2006, 22(4): 254-255. DOI: 10.3969/j.issn.1001-5256.2006.04.005.
|
| [15] |
杨贵敏, 赵运胜, 王春华, 等. 肝细胞癌肿瘤标志物的研究进展[J]. 临床肝胆病杂志, 2018, 34(1): 199-203. DOI: 10.3969/j.issn.1001-5256.2018.01.044.
|
| [16] |
朱明玉, 陈洁, 张欣欣. 肝细胞癌早期诊断血清学标志物的研究进展[J]. 临床肝胆病杂志, 2014, 30(10): 1091-1093. DOI: 10.3969/j.issn.1001-5256.2014.10.029.
|
| [17] |
尹静亚, 王琦. 脂肪因子在非酒精性脂肪性肝病中研究进展[J/CD]. 中国肝脏病杂志(电子版), 2023, 15(1): 1-5. DOI: 10.3969/j.issn.1674-7380.2023.01.001.
|
| [18] |
|
| [19] |
魏思忱, 郑国启. 脂肪因子在肝硬化发病机制中的作用[J]. 临床肝胆病杂志, 2012, 28(1): 78-81.
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
杨子薇, 宋羽霄, 曹春雨, 等. C1q阳性肿瘤相关巨噬细胞影响T细胞代谢及功能的研究进展[J]. 肿瘤学杂志, 2024, 30(11): 907-916. DOI: 10.11735/j.issn.1671-170X.2024.11.B004.
|
杨洋负责设计论文框架,起草和修改论文;王姝涵负责数据收集,统计学分析,绘制图表;金丽莹负责实验操作,研究过程的实施,拟定写作思路,指导撰写文章并最后定稿。
/
| 〈 |
|
〉 |